Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Rovi to make active agents for Moderna COVID-19 vaccine

04/12/2021 | 03:41am EDT

MADRID, April 12 (Reuters) - Spanish pharmaceuticals company Rovi plans to start making the active agents for up to 100 million doses of the COVID-19 vaccine developed by Moderna , it said on Monday without disclosing the size of the investment.

Rovi will start manufacturing of the active agents at its plant in Granada, having previously only packaged vaccines that had been produced in Switzerland, it said in a statement.

Madrid-based Rovi, which already has an agreement with Moderna to fill vials and package its vaccines, expects to start supplying markets other than the United States in the third quarter of 2021, the statement said. (Reporting by Aida Pelaez-Fernandez Editing by Inti Landauro and David Goodman )


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
LABORATORIOS FARMACEUTICOS ROVI, S.A. 2.26% 49.8 Delayed Quote.31.40%
MODERNA, INC. 7.68% 161.38 Delayed Quote.54.48%
All news about MODERNA, INC.
05/15MODERNA  : U.S. CDC Says Administered 270.8 Mln Doses Of COVID-19 Vaccine As Of ..
RE
05/15MODERNA  : U.S. administers 270.8 mln doses of COVID-19 vaccines - CDC
RE
05/14Taiwan tightens curbs after surge in domestic COVID-19 cases
RE
05/14ASTRAZENECA  : Experts call on Canada to use COVAX doses of AstraZeneca or give ..
AQ
05/14Why the CDC Told Fully Vaccinated Americans They Didn't Need to Wear Face Mas..
DJ
05/14MODERNA  : COVID SCIENCE-Delayed 2nd Pfizer/BioNTech shot boosts antibodies in e..
RE
05/14MODERNA  : U.S. administers 268.4 mln doses of COVID-19 vaccines - CDC
RE
05/14MODERNA  : U.S. CDC Says Delivered 341.9 Million Doses Of Covid-19 Vaccine As Of..
RE
05/14PFIZER  : Federal officials lay out road map for post-vaccine life as third wave..
AQ
05/14MODERNA  : The latest news on COVID-19 developments in Canada
AQ
More news
Financials (USD)
Sales 2021 18 363 M - -
Net income 2021 10 203 M - -
Net cash 2021 11 650 M - -
P/E ratio 2021 6,54x
Yield 2021 -
Capitalization 64 799 M 64 799 M -
EV / Sales 2021 2,89x
EV / Sales 2022 2,79x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 166,60 $
Last Close Price 161,38 $
Spread / Highest target 43,1%
Spread / Average Target 3,23%
Spread / Lowest Target -48,6%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.54.48%64 799
LONZA GROUP AG-0.81%46 408
IQVIA HOLDINGS INC.30.62%44 856
CELLTRION, INC.-24.65%32 736
SEAGEN INC.-15.78%26 768
CUREVAC N.V.35.67%21 497